文献速递类风湿关节炎

EULAR/ACR 关于关节痛风险期类风湿关节炎发生的风险分层标准

EULAR/ACR risk stratification criteria for development of rheumatoid arthritis in the risk stage of arthralgia.
PubMed 文献 · Ann Rheum Dis · 2025-05-08

EULAR/ACR 联合专家委员会基于 10 个关节痛队列 2293 例有症状风险个体,开发了用于预测 1 年内进展为临床明显炎性关节炎的风险分层标准。6 个临床和血清学变量组成的标准 AUC 为 0.80(95%CI 0.77-0.83),纳入 MRI 检测的亚临床炎症变量后 AUC 为 0.87(95%CI 0.82-0.90);对 1 年内按 2010 EULAR/ACR 标准发生 RA 的 AUC 为 0.93(95%CI 0.90-0.97)。

要点

  • 6 个临床和血清学变量(晨僵、患者报告关节肿胀、握拳困难、CRP、RF、抗CCP抗体)预测 1 年内炎性关节炎的 AUC 为 0.80。
  • 加入超声变量未提高区分能力;加入 MRI 检测的亚临床炎症变量后 AUC 为 0.87。
  • 同时具备临床、血清学和 MRI 变量时,敏感性和特异性均>75%;预测 RA 发生的 AUC 为 0.93。

核心结论

  • EULAR/ACR 风险分层标准已针对二级医疗中被认为有 RA 风险的关节痛人群开发,可在无影像或有影像数据时应用,旨在为未来预防试验定义同质风险组。

研究设计与样本

  • EULAR/ACR 联合专家委员会研究 10 个关节痛队列(包括临床可疑关节痛和自身抗体阳性关节痛)的风险因素和结局数据,共 2293 例有症状风险个体。
  • 主要结局为 1 年内进展为临床明显炎性关节炎(IA);次要结局为 1 年内按 2010 EULAR/ACR 标准发生 RA。
  • 使用临床和血清学变量(无和有超声或 MRI 检测的亚临床关节炎症)开发风险分层标准。

主要发现

  • 6 个临床和血清学变量(晨僵、患者报告关节肿胀、握拳困难、C反应蛋白、类风湿因子、抗环瓜氨酸肽抗体)预测 IA 发生的 AUC 为 0.80(95%CI 0.77-0.83)。
  • 纳入超声变量未提高区分能力。
  • 纳入 MRI 检测的亚临床炎症变量后 AUC 为 0.87(95%CI 0.82-0.90)。
  • 同时具备临床、血清学和 MRI 变量时,敏感性>75% 且特异性>75%。
  • 对 RA 发生,含 MRI 的标准 AUC 为 0.93(95%CI 0.90-0.97)。

关键数值与推荐

  • 风险分层标准由 6 个临床和血清学变量组成:晨僵、患者报告关节肿胀、握拳困难、C反应蛋白、类风湿因子、抗环瓜氨酸肽抗体。
  • 预测 1 年内 IA 的 AUC:6 变量标准为 0.80(95%CI 0.77-0.83);加入 MRI 变量后为 0.87(95%CI 0.82-0.90)。
  • 预测 1 年内 RA 发生:含 MRI 的标准 AUC 为 0.93(95%CI 0.90-0.97)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The field of rheumatoid arthritis (RA) is moving towards identification of and intervention in people at risk of RA, but a validated risk stratification method is lacking. This work was undertaken to develop a risk stratification method for persons presenting with arthralgia considered to be at risk of RA. METHODS: A joint European Alliance of Associations for Rheumatology (EULAR)/American College of Rheumatology (ACR) expert committee was established. Risk factor and outcome data from 10 arthralgia cohorts (including clinically suspect arthralgia and autoantibody-positive arthralgia) were studied. The work focused on differentiating the risk of progression to clinically apparent inflammatory arthritis (IA) within 1 year, using clinical and serologic variables, without and with subclinical joint inflammation detected by ultrasound (US) or magnetic resonance imaging (MRI). Developing RA according to the 2010 EULAR/ACR criteria within 1 year was a secondary outcome. A set of validated risk stratification criteria was developed. RESULTS: Using data from 2293 symptomatic at-risk individuals, a stratification method was derived consisting of 6 clinical and serologic variables (morning stiffness, patient-reported joint swelling, difficulty making a fist, C-reactive protein, rheumatoid factor, and anti-citrullinated peptide antibody) yielding an area under the curve (AUC) of 0.80 (95% CI, 0.77-0.83) for IA development. The inclusion of US variables did not increase the discriminative ability. When MRI-detected subclinical inflammation variables were included, the AUC was 0.87 (95% CI, 0.82-0.90). In the presence of clinical, serologic, and MRI variables, a sensitivity and specificity of >75% was achieved. For RA development, the AUC of the criteria with MRI was 0.93 (95% CI, 0.90-0.97). CONCLUSIONS: EULAR/ACR risk stratification criteria have been developed for people with arthralgia in secondary care who are considered at risk for RA. They can be applied in the absence or presence of imaging data and have been developed to define homogeneous risk groups for future prevention trials.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. van Steenbergen HW, Doornkamp F, Alivernini S, et al. EULAR/ACR risk stratification criteria for development of rheumatoid arthritis in the risk stage of arthralgia. Ann Rheum Dis. 2025. PMID: 40447498. doi:10.1016/j.ard.2025.01.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。